TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Maia Biotechnology
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

MAIA Biotechnology is developing ateganosine, a novel telomere-targeting cancer therapy for non-small cell lung cancer patients who do not respond to existing treatments, with potential to address a significant unmet medical need.

Insights
SOUNW   neutral

Briefly mentioned as an AI software company trading at expensive valuations


MAIA   positive

Company is developing a potentially groundbreaking first-in-class therapy targeting a large unmet medical need, with FDA Fast Track Designation and promising clinical trial progress